Cannabis Firm Cresco Labs Reports Mixed Q4, CEO Says Company Will 'Strategically Deploy Capital To Create Growth' In 2025

Cresco Labs Inc. CRLBF reported on Wednesday a fourth-quarter revenue of $175.91 million, down from $188.24 million a year ago, beating the consensus of $172.13 million.

Fourth quarter operating cash flow stood at $29 million, with free cash flow of $27 million.

Also Read: Cannabis Stock Valuations Reflect No Expectation Of Federal Reform: Study

“In 2024, the team executed with discipline — streamlining operations, prioritizing profitability and generating record free cash flow,” said Charlie Bachtell, Cresco Labs CEO and co-founder. “In 2025, we’re extending our focus to strategically deploy capital to create growth and maximize returns for the years ahead. It’s a straightforward approach: execute at the highest level, generate cash, reinvest in high-ROI opportunities, and repeat.”

Gross margin fell from 51.1% to 47.8%. Adjusted gross profit was $87 million, with a gross margin of 49.5%, down from 53% year-over-year.

Operating profit fell from $27.09 million to $19.41 million.

Fourth quarter Adjusted EBITDA reached $42 million, with a margin of 24%.

Earlier this week, the vertically integrated cannabis and medical marijuana company announced its management services agreement with a Tier 3 Cultivation License in Kentucky.

The agreement entitles Cresco Labs to manage and operate a cultivation facility with up to 25,000 square feet of canopy, marking a significant milestone for the company and establishing Cresco Labs as one of only two operators of Kentucky’s coveted Tier 3 cultivation licenses.

CRLBF Price Action: Cresco Labs is down 0.13% at 74 cents at publication Wednesday.

Read Next:

Photo: Plateresca via Shutterstock